Measuring quality and keeping the protein stable

📍 Where we are: Part 8 of the journey — before we build the factory, we learn how to measure quality and keep the protein safe.

By now we have a cell that makes our antibody. But two big questions remain: How do we prove it is the right, working medicine? And how do we keep that fragile protein from falling apart on the shelf? This chapter is about those two jobs.

The simple version

Think of a food product. It needs a nutrition label so you can check exactly what is inside — and it needs the right preservatives and packaging so it stays fresh and safe until someone eats it. Analytical development writes the label. Formulation development keeps the medicine fresh.

What actually happens

These two jobs run side by side. Let's take them one at a time.

Job 1: Analytical development (writing the tests). There is a saying in this work: you cannot improve what you cannot measure. So scientists build a toolbox of assays (tests) that answer four questions about the antibody:

1. Identity — is this actually the right antibody, and not something else?
2. Purity — how clean is it? In particular, how much has clumped into aggregates (proteins stuck together, which the body can react badly to) or carries leftover impurities?
3. Potency — does it actually work? A potency test checks that the antibody still grabs its target the way the medicine is supposed to.
4. Structure — the fine details, including glycans: tiny sugar chains attached to the antibody. Glycans are like trim on a car — they change how the antibody behaves in the body, so they must be watched closely.

To see these things, scientists use instruments like HPLC (high-performance liquid chromatography, which separates a mixture so you can count each piece) and LC-MS (liquid chromatography paired with mass spectrometry, which weighs molecules so precisely it can confirm the exact protein).

The properties that truly matter for safety and effectiveness — and that must be kept inside set limits — are named the Critical Quality Attributes (CQAs). The CQA list becomes the medicine's definition of "good."

Job 2: Formulation development (keeping it stable). A protein is delicate. Heat, shaking, freezing, or the wrong liquid can make it unfold (lose its shape) or aggregate (clump). A clumped antibody does not work and can be dangerous. So formulators design the protein's home:

They pick a gentle buffer (a liquid that holds the acidity steady) and add excipients — stabilizing ingredients such as sugars, surfactants (soap-like molecules that stop the protein sticking to surfaces and foaming), and salts. They tune the concentration. They decide whether the product ships as a ready-to-use liquid or is freeze-dried (lyophilized — water removed to a dry cake that lasts longer and is mixed with water before use).

Then they run stability studies: real samples are stored at different temperatures, from cold to deliberately warm, and tested over weeks and months. This is how a team proves a real shelf life, such as "stable for two years at 2 to 8 °C."

Why it matters

These two jobs decide whether the medicine is both correct and durable.

Without good assays, you are flying blind — a bad batch could reach a patient unnoticed. The CQAs defined here are the exact yardsticks the factory will use later at quality control and release to decide if a batch can ship. Get the CQA list wrong, and the whole control system points at the wrong things.

Without good formulation, even a perfect antibody can clump in the vial during shipping and become useless or unsafe. Aggregates are a real risk: the immune system may attack them, which can hurt the patient. So formulation is not decoration — it is part of the safety promise.

In the real world

Most biologic medicines are tested with a shared analytical "platform" — HPLC and LC-MS methods that teams reuse across many antibodies, then customize. The information these tests produce also feeds the recipe-building work in process development, because you tune a process by measuring what it produces.

A newer direction is to measure quality during manufacturing rather than only afterward, using PAT (process analytical technology) — sensors and at-line instruments that watch CQAs in near real time. This continuous-monitoring mindset is central to the modern, intensified processing that the U.S. NIIMBL institute and its SABRE pilot facility are advancing.

Key terms

• Assay — a laboratory test that measures a specific property of the medicine.
• Critical Quality Attribute (CQA) — a property that must stay within set limits to keep the medicine safe and effective.
• Identity / purity / potency — is it the right antibody, how clean is it, and does it work.
• Aggregate — proteins clumped together; unwanted and potentially unsafe.
• Glycan — a sugar chain on the antibody that affects how it behaves in the body.
• HPLC — a method that separates a mixture so each component can be measured.
• LC-MS — liquid chromatography plus mass spectrometry, which weighs molecules to confirm the protein.
• Formulation — the buffer, excipients, and concentration chosen to keep the protein stable.
• Excipient — a stabilizing ingredient (sugar, surfactant, or salt) added to the medicine.
• Lyophilization — freeze-drying the medicine into a dry cake for a longer shelf life.
• Stability study — storing samples over time at various temperatures to prove shelf life.
• PAT (process analytical technology) — tools that measure quality during manufacturing, not only after.